Participated · Seed · Apr 2026

ViewsML develops an AI-driven virtual biomarker staining platform that virtualizes immunohistochemistry to deliver per-cell spatial biomarker insights from standard H&E slides. The platform is intended to preserve scarce tissue samples while accelerating research, clinical trials, and patient care. ViewsML is building a virtual biomarker library comprised of AI models that extract biomarker information directly from routine pathology images. The company has established strategic collaborations with healthcare institutions, diagnostic companies, and biopharma organizations to drive adoption across research and clinical applications. Led by CEO Kenneth To, ViewsML plans to use newly raised seed capital to commercialize the platform, expand partnerships, advance clinical validation of its virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

Participated · Series A · Oct 2025

Ampa develops the Ampa One, an FDA-cleared, portable transcranial magnetic stimulation (TMS) system designed for simplicity and scalability. The company says the device fits in the trunk of a car, costs $3,000 per month, can be operated after a few hours of training, and features a lightweight hand-holdable coil, camera-guided targeting, and pre-printed neuronavigation caps. Ampa reports the Ampa One is already in use at clinics across more than 30 U.S. states and that demand has doubled every quarter. The company secured regulatory approval in Israel and plans commercial launch overseas. Leadership cited in the announcement includes co-founder Jonathan Downar, MD, PhD, and CEO Don Vaughn, PhD. Ampa positions the product as a lower-cost, higher-throughput option for clinics and is using recent financing to accelerate rollout and meet accelerating demand.

Participated · Series A · Jan 2025

Immunis is a clinical-stage biotechnology company developing stem cell‑derived, multi-active biologics using its multi-active secretome technology to deliver natural human immune modulators. Its lead investigational product, IMM01‑STEM, is being developed to address age-related muscle atrophy and metabolic dysfunction in elderly patients. A Phase 1/2a trial in nine elderly patients showed safety, tolerability and suggestive efficacy, including improvements in quality-of-life measures and gait speed. Preclinical studies in aged mouse models published in GeroScience and Aging Cell showed reversal of muscle atrophy, improved muscle function, enhanced metabolism and reduced body and liver fat. The company describes itself as the leading biotech with the most advanced stem cell‑derived multi-active biologic in human clinical trials. The recently closed financing will fund two Phase 2 clinical trials to further test IMM01‑STEM’s efficacy in targeted elderly populations. Immunis is a private biotech developing a novel immunomodulatory secretome product line (STEM) to address age- and disease-related immune decline. The STEM product line leverages stem cell technology to deliver all-natural, all-human immune modulators in their natural, relative physiological concentrations. Its lead secretome treatment, IMM01-STEM, is described as using natural immunomodulators with potent cytoskeletal remodeling properties. The company plans to use the new funding to support clinical assessment of IMM01-STEM in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy. The trial targets muscle atrophy, a condition the article states is experienced by 100% of the population in age, disuse, and disease contexts. Immunis is based in Irvine, California.

Participated · Seed · Sep 2024

CardiaTec is a Cambridge University spinout that applies AI and multi-omics analysis to discover novel treatments for cardiovascular disease. The company aggregates human heart tissue data from 65 hospitals across the U.K. and the U.S. to build what it calls the largest human heart tissue multi-omics dataset. Its platform integrates genetics, epigenetics, gene expression, and protein data to identify disease mechanisms and therapeutic targets. CardiaTec was founded in 2021 and is led by CEO Raphael Peralta, COO Thelma Zablocki, and CTO Namshik Han. With an eight-person team in Cambridge, the company plans wet-lab validation of targets and to begin identifying and testing drug candidates over the coming years. Financially, CardiaTec had previously raised $1.8 million in pre-seed funding and has just completed a new seed round to fund data collection and validation work. CardiaTec Biosciences develops a proprietary AI-driven target discovery platform that analyzes large-scale multiomic cardiovascular data. Its platform links gene variation, methylation, expression, proteomic and metabolomic signals to reveal systems-level relationships in disease. The company aims to accelerate drug discovery, reduce costs, and deliver new compounds to help patients. CardiaTec was founded in 2021 by Raphael Peralta, Thelma Zablocki, and Dr. Namshik Han and is based in Cambridge, MA. In July 2022 it raised £1.4M in a pre-seed round to fund continued development. The funds will be used to advance the platform and unearth new treatments for cardiovascular patients.

Participated · Series A · Aug 2022

Biotia is a New York, NY health tech company that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Launched from the Jacobs Technion-Cornell Institute at Cornell Tech, Biotia operates a SUNY Downstate-affiliated CLIA lab at BioBAT in New York City. Its products include a curated genomics reference library for pathogens, clinical-grade metagenomics assays, and a sequencing-based assay to detect SARS-CoV-2 variants that recently received expanded FDA EUA. The company provides software, data, and lab assays to clinicians, laboratories, and public-health organizations for pathogen detection, characterization, research, and surveillance. Biotia plans to grow its diagnostic offerings and expand capacity for global pathogen research and surveillance while rolling out new algorithms and tools for physicians, researchers, and health systems. Financially, Biotia has raised an oversubscribed $8 million Series A and will use the investment to expand technical capabilities, compliance, and marketing reach. Biotia leverages next-generation DNA sequencing (NGS) and proprietary AI software Chelsea™ to rapidly and accurately identify microorganisms and antimicrobial resistance from clinical and environmental samples. Chelsea can detect known and emerging bacteria, fungi, parasites and viruses from a clinically‑curated and annotated database of over 16,000 microbial species and reports predicted drug resistance and virulence markers. The company has built one of the world’s largest precision metagenomics clinical databases by working with hospitals internationally across sample types including urine, stool, blood, sputum and soft tissue. Biotia plans to launch new CAP/CLIA clinical diagnostic tests in early 2020 and is expanding its offerings from environmental testing and research‑use patient tests to patient diagnostics. The company announced an oversubscribed $2.4M seed raise to further develop and implement its diagnostic testing methods and AI software. The executive team includes Co‑Founder and CEO Dr. Niamh B. O’Hara, Co‑Founder Dr. Christopher E. Mason (Global Director), Co‑Founder and CTO Dr. Rachid Ounit, and Chief Medical Officer Dr. Dorottya Nagy‑Szakal.